Treatment Resistant DepressionDOSNCT06730841
Dose-Optimized and Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
A study testing Dose-Optimized and Spaced Transcranial Direct Current Stimulation and Spaced Transcranial Direct Current Stimulation in people with Treatment Resistant Depression and Major Depressive Disorder, run by University of California, San Diego at 1 site in United States.
Trial summary
This study aims to evaluate the feasibility, safety, and tolerability of an innovative approach to treating Major Depressive Disorder (MDD), particularly in cases where patients have not responded well to traditional therapies. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Treatment Resistant Depression, Major Depressive Disorder
- What is being tested?
- Dose-Optimized and Spaced Transcranial Direct Current Stimulation and Spaced Transcranial Direct Current Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Sep 2024to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- People between the ages of 18 and 85 at the time of screening.
- Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
- Currently diagnosed with Major Depressive Disorder (MDD) and meets criteria for a Major Depressive Episode, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).
- Medical records confirming a history of at least moderate treatment-resistance as defined an Antidepressant Treatment History Form (ATHF) score for that antidepressant trial of > 2 in the current episode OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF score of 1 or 2 on those 2 separate antidepressants) OR have a combination of one failed trial and one not tolerated trial, per the definitions above.
- MADRS score of ≥20 at screening (Visit 1).
Show all 12Show fewer
- Existing relationship with mental health provider and access to ongoing psychiatric care before and after completion of the study.
- Must be on a stable antidepressant therapeutic regimen, or not receiving treatment for 4 weeks prior to study enrollment and agree to continue this regimen throughout the study period.
- In good general health, as evidenced by medical history.
- For persons of child-bearing potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
- Agreement to adhere to Lifestyle Considerations (i.e. must continue with any existing treatments) throughout study duration.
- For persons of child-bearing potential: must take a pregnancy test at the screening visit, with results confirmed as negative by study staff.
Who cannot join
- An individual will be excluded from participation in this study if they meet any of the following criteria, as determined from a review of medical records prior to screening or at the screening visit:
- Pregnancy;
- History of psychotic or bipolar disorder or depression with psychotic features;
- Significant borderline personality disorder;
- Significant comorbid obsessive-compulsive or post-traumatic stress disorder;
- Previously diagnosed Intellectual Disability or Autism Spectrum Disorder;
Show all 23Show fewer
- Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal;
- Clinically significant suicidality;
- Any history of tDCS;
- Any history of ECT;
- History of TMS (greater than 15 sessions) without a clinically meaningful response.
- History of ketamine (greater than 4 sessions) without a clinically meaningful response;
- Chronic depression (defined as of over 5 years duration);
- History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent symptoms;
- Untreated or insufficiently treated endocrine disorder;
- Contraindication to receiving tDCS (e.g., ferromagnetic implant, history of seizure, known brain lesion);
- Treatment with an investigational drug or other intervention within the study period;
- Unstable symptoms between screening and baseline as defined by a ≥ 30% change in MADRS score;
- Require a benzodiazepine with a dose > lorazepam 2 mg/day
- Has started a new psychotherapeutic process in the past 3 months from screening;
- Use of potentially irritant topical treatments (ex: retinoids, alpha hydroxy acids)
- Aesthetic procedure the area of the forehead directly below the stimulation area within the last 6 months (laser, fillers, surgery, etc.)
- Any active dermatological condition on face or scalp that would in the opinion of the PI represent a contraindication to the treatment.
Trial locations and contacts
1 site in 1 country.
United States1 site
UCSD Interventional Psychiatry
San Diego, California, 92127
About this study
This study aims to evaluate the feasibility, safety, and tolerability of an innovative approach to treating Major Depressive Disorder (MDD), particularly in cases where patients have not responded well to traditional therapies. Specifically, the objective is to evaluate the antidepressant effects of a Dose-Optimized and Spaced Transcranial Direct Current Stimulation (DOS-tDCS) protocol in participants with treatment-resistant depression (TRD) compared to spaced tDCS only and sham tDCS in a 3-arm randomized controlled trial (RCT). The proposed method involves applying low-intensity electrical currents through the scalp in a manner that is both more intense and more frequently spaced than standard treatments. This approach is hypothesized to lead to a significant reduction in depressive symptoms. Participants in the study will be randomly assigned to one of three groups: the experimental group receiving the DOS-tDCS treatment, a group receiving spaced tDCS only, or a control group receiving a sham (placebo) treatment. Outcomes will be measured over a period of six weeks. The study's goal is to offer a potentially more accessible and effective treatment option for individuals who have not benefited from existing MDD therapies.
- Being tested
- Dose-Optimized and Spaced Transcranial Direct Current Stimulation, Spaced Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation
- Medical subject headings
- Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dose-Optimized and Spaced Transcranial Direct Current StimulationDevice
Also called tDCS, Soterix Medical 1x1 CT
tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA).
Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total).
Spaced Transcranial Direct Current StimulationDevice
Also called Soterix Medical 1x1 CT
tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA.
Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total).
Sham Transcranial Direct Current StimulationDevice
Also called Soterix Medical 1x1 CT
tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation.
Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total).
| Study group | Role | What they receive |
|---|---|---|
| DOS-tDCS: A dose-optimized and spaced form of tDCS | Active comparator | On each treatment day, participants will receive 5 tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. The dose-optimized and spaced tDCS (DOS-tDCS) group will be treated using a stimulation intensity of up to 4 mA. Receives: Device: Dose-Optimized and Spaced Transcranial Direct Current Stimulation |
| Spaced tDCS: A spaced form of tDCS only | Active comparator | On each treatment day, participants will receive 5 tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. The spaced tDCS only group will receive stimulation at the standard 2 mA dose. Receives: Device: Spaced Transcranial Direct Current Stimulation |
| Sham tDCS | Sham comparator | On each treatment day, participants will receive 5 sham tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. Receives: Device: Sham Transcranial Direct Current Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility (Recruitment)
Recruitment rate will be measured as the number of patients enrolled by the conclusion of the study, reported as a whole number.
Measured: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Feasibility (Retention)
Retention rate will be measured as the percentage of enrolled patients who complete all study visits, reported as a percentage.
Measured: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Feasibility (Adherence)
The proportion of completed sessions relative to the total prescribed sessions, expressed as a percentage.
Measured: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Safety
Safety will be measured by the number of serious adverse events (SAEs).
Measured: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Tolerability
Tolerability will be measured by the number of adverse events (AEs).
Measured: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Secondary outcomes (8)
Biomarker Discovery: Short-Interval Intracortical Inhibition (SICI) via TMS-EMG
TMS-EMG will be used to evaluate changes in SICI.
Unit of Measurement: Amplitude or percentage inhibition.
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Intracortical Facilitation (ICF) via TMS-EMG
TMS-EMG will be used to evaluate changes in intracortical facilitation
Unit of Measurement: Amplitude or percentage facilitation.
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Cortical Silent Period (CSP) via Transcranial Magnetic Stimulation-Electromyography (TMS-EMG)
TMS-EMG will be used to assess changes in the cortical silent period (CSP).
Unit of Measurement: Duration (milliseconds).
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: TMS-Evoked Potential (TEP) Component Amplitudes via TMS-EEG
TMS-EEG will be used to evaluate changes in TMS-evoked potential (TEP) component amplitudes.
Unit of Measurement: Voltage (µV).
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Significant Current Density (SCD) via TMS-EEG
TMS-EEG will be used to evaluate changes in significant current density (SCD).
Unit of Measurement: Current density (A/m²).
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Biomarker Discovery: Significant Current Scattering (SCS) via TMS-EEG
TMS-EEG will be used to evaluate changes in significant current scattering (SCS).
Unit of Measurement: Scattering coefficient (unitless).
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Resting-State Electroencephalography (rsEEG)
rsEEG will be used to analyze changes in brain activity patterns at rest.
Unit of Measurement: Frequency (Hz) and amplitude (µV).
Measured: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Changes from pre-treatment depressive symptomatology in post-treatment
Changes in depressive symptoms will be assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), which ranges from 0 to 60, with higher scores indicating more severe depression. A decrease in the MADRS score will be interpreted as an improvement in symptoms.
Measured: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2024
- Study start26 Sep 2024
- Primary completion1 Aug 2025
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Treatment Resistant DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 3 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Diego
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jean-Philippe Miron, University of California, San Diego
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06730841
- Sponsor's protocol ID
- 810432
- Acronym
- DOS
- Status last verified
- Dec 2024
- First submitted
- 23 Aug 2024
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-Optimized and Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
- ClinicalTrials.gov ID
- NCT06730841
- Acronym / sponsor ID
- DOS / 810432
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3 participants (actual)
- Lead sponsor
- University of California, San DiegoUniversity, hospital or other
- Study start
- 26 Sep 2024 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Sep 2025 (actual)
- First posted
- 12 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the feasibility, safety, and tolerability of an innovative approach to treating Major Depressive Disorder (MDD), particularly in cases where patients have not responded well to traditional therapies. Specifically, the objective is to evaluate the antidepressant effects of a Dose-Optimized and Spaced Transcranial Direct Current Stimulation (DOS-tDCS) protocol in participants with treatment-resistant depression (TRD) compared to spaced tDCS only and sham tDCS in a 3-arm randomized controlled trial (RCT). The proposed method involves applying low-intensity electrical currents through the scalp in a manner that is both more intense and more frequently spaced than standard treatments. This approach is hypothesized to lead to a significant reduction in depressive symptoms. Participants in the study will be randomly assigned to one of three groups: the experimental group receiving the DOS-tDCS treatment, a group receiving spaced tDCS only, or a control group receiving a sham (placebo) treatment. Outcomes will be measured over a period of six weeks. The study's goal is to offer a potentially more accessible and effective treatment option for individuals who have not benefited from existing MDD therapies.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| DOS-tDCS: A dose-optimized and spaced form of tDCS | Active comparator | Device: Dose-Optimized and Spaced Transcranial Direct Current StimulationOn each treatment day, participants will receive 5 tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. The dose-optimized and spaced tDCS (DOS-tDCS) group will be treated using a stimulation intensity of up to 4 mA. |
| Spaced tDCS: A spaced form of tDCS only | Active comparator | Device: Spaced Transcranial Direct Current StimulationOn each treatment day, participants will receive 5 tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. The spaced tDCS only group will receive stimulation at the standard 2 mA dose. |
| Sham tDCS | Sham comparator | Device: Sham Transcranial Direct Current StimulationOn each treatment day, participants will receive 5 sham tDCS sessions, each lasting 20 minutes, with a 20-minute intersession interval. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- People between the ages of 18 and 85 at the time of screening.
- Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.
- Currently diagnosed with Major Depressive Disorder (MDD) and meets criteria for a Major Depressive Episode, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).
- Medical records confirming a history of at least moderate treatment-resistance as defined an Antidepressant Treatment History Form (ATHF) score for that antidepressant trial of > 2 in the current episode OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF score of 1 or 2 on those 2 separate antidepressants) OR have a combination of one failed trial and one not tolerated trial, per the definitions above.
Key exclusion criteria (23 listed)
- An individual will be excluded from participation in this study if they meet any of the following criteria, as determined from a review of medical records prior to screening or at the screening visit:
- Pregnancy;
- History of psychotic or bipolar disorder or depression with psychotic features;
- Significant borderline personality disorder;
- Significant comorbid obsessive-compulsive or post-traumatic stress disorder;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dose-Optimized and Spaced Transcranial Direct Current StimulationAlso: tDCS, Soterix Medical 1x1 CTtDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA). Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total). | Device | DOS-tDCS: A dose-optimized and spaced form of tDCS |
| Spaced Transcranial Direct Current StimulationAlso: Soterix Medical 1x1 CTtDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA. Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total). | Device | Spaced tDCS: A spaced form of tDCS only |
| Sham Transcranial Direct Current StimulationAlso: Soterix Medical 1x1 CTtDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation. Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total). | Device | Sham tDCS |
Primary outcome
Feasibility (Recruitment)
Time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Recruitment rate will be measured as the number of patients enrolled by the conclusion of the study, reported as a whole number.
Feasibility (Retention)
Time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Retention rate will be measured as the percentage of enrolled patients who complete all study visits, reported as a percentage.
Feasibility (Adherence)
Time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
The proportion of completed sessions relative to the total prescribed sessions, expressed as a percentage.
Safety
Time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Safety will be measured by the number of serious adverse events (SAEs).
Tolerability
Time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Tolerability will be measured by the number of adverse events (AEs).
8 secondary outcomes
Biomarker Discovery: Short-Interval Intracortical Inhibition (SICI) via TMS-EMG
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Intracortical Facilitation (ICF) via TMS-EMG
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Cortical Silent Period (CSP) via Transcranial Magnetic Stimulation-Electromyography (TMS-EMG)
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: TMS-Evoked Potential (TEP) Component Amplitudes via TMS-EEG
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Significant Current Density (SCD) via TMS-EEG
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Biomarker Discovery: Significant Current Scattering (SCS) via TMS-EEG
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Biomarker Discovery: Resting-State Electroencephalography (rsEEG)
Time frame: From baseline neurophysiological assessment prior to treatment, to during treatment, to 6 weeks after first treatment.
Changes from pre-treatment depressive symptomatology in post-treatment
Time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Treatment Resistant Depression
RecruitingPhase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Depression, Major Depressive Disorder
Recruiting
SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant Depression
Depressive Disorder, Treatment-Resistant, Memory Deficits
Recruiting
rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression
Depression, Treatment Resistant
Recruiting
Ketogenic Diet and Neuromodulation in Treatment Resistant Depression
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Active, not recruitingPhase 1
Psilocybin for Treatment-Resistant Depression in Autism
Treatment Resistant Depression, Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dose-Optimized and Spaced Transcranial Direct Current Stimulation and Spaced Transcranial Direct Current Stimulation in people with Treatment Resistant Depression and Major Depressive Disorder, run by University of California, San Diego at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility (Recruitment) (time frame: From baseline clinical assessment prior to treatment, to 6 weeks after first treatment.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.